Colleen Marshall
Payments from drug & device makers
Across 122 payments — averaging $85.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$9K
- Otsuka America Pharmaceutical, Inc.$392
- Neurocrine Biosciences, Inc.$221
- Alkermes, Inc.$153
- Teva Pharmaceuticals USA, Inc.$150
- E.r. Squibb & Sons, L.L.C.$138
- plus $214 from 5 others
What the payments were for
- Consulting fees$4,96047%
- Travel & lodging$2,48124%
- Food & beverage$3,02829%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 71 | $9,201 |
| Otsuka America Pharmaceutical, Inc. | 17 | $392 |
| Neurocrine Biosciences, Inc. | 6 | $221 |
| Alkermes, Inc. | 7 | $153 |
| Teva Pharmaceuticals USA, Inc. | 3 | $150 |
| E.r. Squibb & Sons, L.L.C. | 8 | $138 |
| Lundbeck LLC | 4 | $80 |
| Axsome Therapeutics, Inc. | 2 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Johnson & Johnson | 1 | $25 |
| Atricure, Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$8,144
- ABILIFY MAINTENA$125
- ABILIFY ASIMTUFII$125
- REXULTI$125
- Austedo XR$122
- INGREZZA$119
How this compares
$10,469 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 12 | $121 |
| Prednisone | 11 | $17 |
Paid to pharmacies, not to this prescriber.
Other family in Enola
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Jessica LindenbergerPittsburgh$131K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.